Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- United States Supreme Court (2)
- Affordable Care Act (ACA) (1)
- Antitrust Division (1)
- Biologics (1)
- Biosimilars (1)
-
- Cady Roberts & Company (1)
- Congress (1)
- Criminal Division (1)
- Criminal liability (1)
- Criminal prosecution of corporations (1)
- Deferred prosecution (1)
- Department of Health and Human Services (HHS) (1)
- Deterrent value (1)
- Executive agency (1)
- Expressive theory (1)
- Expressive value (1)
- FTC Commissioner (1)
- Federal Trade Commission Act (1)
- Food and Drug Administration (1)
- Global financial crisis (1)
- Health care reform (1)
- Healthcare insurer settlements (1)
- Humphrey (William E.) (1)
- Humphrey’s Executor v. United States (1)
- Incentives (1)
- Insider trading (1)
- Interstate Commerce Commission (1)
- Justice Department (1)
- Moral content (1)
- Myers v. United States (1)
Articles 1 - 5 of 5
Full-Text Articles in Law
Trouble On The Exchanges — Does The United Owe Billions To Health Insurers?, Nicholas Bagley
Trouble On The Exchanges — Does The United Owe Billions To Health Insurers?, Nicholas Bagley
Articles
Yet another bruising fight has erupted over health care reform. On September 9, 2016, the Obama administration offered to open settlement negotiations with health insurers that have sued the United States to recover billions of dollars that they claim they are owed. Congressional Republicans are incensed, believing that any settlement would illegally squander taxpayer dollars in a lastgasp effort to save the Affordable Care Act (ACA).
The Sec, Administrative Usurpation, And Insider Trading, Adam C. Pritchard
The Sec, Administrative Usurpation, And Insider Trading, Adam C. Pritchard
Articles
The history of insider trading law is a tale of administrative usurpation and legislative acquiescence. Congress has never enacted a prohibition against insider trading, much less defined it. Instead, the SEC has led in defining insider trading, albeit without the formality of rulemaking, and subject to varying degrees of oversight by the courts. The reason why lies in the deference that the Supreme Court gave to the SEC in its formative years. The roots of insider trading law are commonly traced to the SEC’s decision in Cady, Roberts & Co. Cady, Roberts was only made possible, however, by the …
Manufacturing Barriers To Biologics Competition And Innovation, W. Nicholson Price Ii., Arti K. Rai
Manufacturing Barriers To Biologics Competition And Innovation, W. Nicholson Price Ii., Arti K. Rai
Articles
As finding breakthrough small-molecule drugs becomes more difficult, drug companies are increasingly turning to "large molecule" biologics. Although biologics represent many of the most promising new therapies for previously intractable diseases, they are extremely expensive. Moreover, the pathway for generic-type competition set up by Congress in 2010 is unlikely to yield significant cost savings. This Article provides a fresh diagnosis of and prescription for this major public policy problem. It argues that the key cause is pervasive trade secrecy in the complex area of biologics manufacturing. Under the current regime, this trade secrecy, combined with certain features of Food and …
Debunking Humphrey's Executor, Daniel A. Crane
Debunking Humphrey's Executor, Daniel A. Crane
Articles
The Supreme Court’s 1935 Humphrey’s Executor decision paved the way for the modern administrative state by holding that Congress could constitutionally limit the President’s powers to remove heads of regulatory agencies. The Court articulated a quartet of features of the Federal Trade Commission’s (“FTC”) statutory design that ostensibly justified the Commission’s constitutional independence. It was to be nonpartisan and apolitical, uniquely expert, and performing quasi-legislative and quasi-judicial, rather than executive, functions. In recent years, the staying power of Humphrey’s Executor has been called into question as a matter of constitutional design. This Essay reconsiders Humphrey’s Executor from a different angle. …
The Pendulum Swings: Reconsidering Corporate Criminal Prosecution, David M. Uhlmann
The Pendulum Swings: Reconsidering Corporate Criminal Prosecution, David M. Uhlmann
Articles
Corporate crime continues to occur at an alarming rate, yet disagreement persists among scholars and practitioners about the role of corporate criminal prosecution. Some argue that corporations should face criminal prosecution for their misconduct, while others would reserve criminal prosecution for individual corporate officials. Perhaps as a result of this conflict, there has been a dramatic increase over the last decade in the use of deferred prosecution and non-prosecution agreements for some corporate crimes, even as the government continues to bring criminal charges for other corporate crimes. To move beyond our erratic approach to corporate crime, we need a better …